*Movement Disorders Center, TWH, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada; †Departments of Neurology, and ‡Internal Medicine, Catholic University of Sacred Heart, Gemelli University Hospital, Rome, Italy; §Department of Pharmacology, Catholic University of Sacred Heart, Rome, Italy; and ||Medical Direction, Chiesi Farmaceutici, Parma, Italy.
Conflicts of Interest and Source of Funding: Alfonso Fasano received an unrestricted grant from Chiesi Farmaceutici and a grant from AFaR (Rome, Italy) for this study. Alfonso Fasano and Anna Rita Bentivoglio received speaker’s fees from Chiesi Farmaceutici, which produces and sells levodopa methylester in Italy. Stefano Marconi is currently an employee of Chiesi Farmaceutici, which produces and sells levodopa methylester in Italy. The remaining authors have no conflicts of interest to declare.
Address correspondence and reprint requests to Alfonso Fasano, MD, PhD, Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St, 7 Mc412, Toronto, ON Canada M5T 2S8; E-mail: [email protected]